Robert R Henry, Paresh Dandona, Jeremy Pettus, Sunder Mudaliar, John Xu, Lars Hansen. Diabetes Obes Metab 2017
Times Cited: 29
Times Cited: 29
Anne L Peters, Robert R Henry, Payal Thakkar, Cindy Tong, Maria Alba. Diabetes Care 2016
Times Cited: 62
Times Cited: 62
List of shared articles
Times cited
Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials.
Yuxin Huang, Zeju Jiang, Yiping Wei. Exp Ther Med 2021
Yuxin Huang, Zeju Jiang, Yiping Wei. Exp Ther Med 2021
Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Schafer Boeder, Steven V Edelman. Diabetes Obes Metab 2019
Schafer Boeder, Steven V Edelman. Diabetes Obes Metab 2019
Efficacy of dapagliflozin as an adjunct therapy in patients with inadequately controlled type 1 diabetes mellitus.
Laura Van den Mooter, Simon Caerels, Chantal Mathieu. Expert Opin Pharmacother 2018
Laura Van den Mooter, Simon Caerels, Chantal Mathieu. Expert Opin Pharmacother 2018
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
Claire Baker, Suman Wason, Phillip Banks, Sangeeta Sawhney, Anna Chang, Thomas Danne, Diane Gesty-Palmer, Jake A Kushner, Darren K McGuire, Frank Mikell,[...]. Diabetes Obes Metab 2019
Claire Baker, Suman Wason, Phillip Banks, Sangeeta Sawhney, Anna Chang, Thomas Danne, Diane Gesty-Palmer, Jake A Kushner, Darren K McGuire, Frank Mikell,[...]. Diabetes Obes Metab 2019
Dapagliflozin for the treatment of type 1 diabetes mellitus.
Kalliopi Pafili, Efstratios Maltezos, Nikolaos Papanas. Expert Opin Investig Drugs 2017
Kalliopi Pafili, Efstratios Maltezos, Nikolaos Papanas. Expert Opin Investig Drugs 2017
Sodium-glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis in patients with type 1 diabetes: Metabolic imbalance as an underlying mechanism.
Wataru Ogawa, Yushi Hirota. J Diabetes Investig 2019
Wataru Ogawa, Yushi Hirota. J Diabetes Investig 2019
Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
Tomohide Yamada, Nobuhiro Shojima, Hisashi Noma, Toshimasa Yamauchi, Takashi Kadowaki. Diabetes Obes Metab 2018
Tomohide Yamada, Nobuhiro Shojima, Hisashi Noma, Toshimasa Yamauchi, Takashi Kadowaki. Diabetes Obes Metab 2018
SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
Halis Kaan Akturk, Amanda Rewers, Satish K Garg. Curr Opin Endocrinol Diabetes Obes 2018
Halis Kaan Akturk, Amanda Rewers, Satish K Garg. Curr Opin Endocrinol Diabetes Obes 2018
Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Giovanni Musso, Antonio Sircana, Francesca Saba, Maurizio Cassader, Roberto Gambino. PLoS Med 2020
Giovanni Musso, Antonio Sircana, Francesca Saba, Maurizio Cassader, Roberto Gambino. PLoS Med 2020